The purpose of this study is to evaluate novel KarX and KarT prototypes versus the KarXT and KarX-EC reference following single doses, and to explore the effect of food after multiple doses of selected prototypes in healthy adult participants.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Maximum observed concentration (Cmax)
Timeframe: Up to Day 23
Time of maximum observed concentration (Tmax)
Timeframe: Up to Day 23
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Timeframe: Up to Day 23
Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
Timeframe: Up to Day 23
Area under the concentration-time curve in 1 dosing interval (AUC(TAU))
Timeframe: Up to Day 23
Concentration at the end of a dosing interval (Ctau)
Timeframe: Up to Day 23
Apparent total body clearance (CLT/F)
Timeframe: Up to Day 23
Effective elimination half-life during dosing interval (T-HALF(eff))
Timeframe: Up to Day 23
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com